Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 38

1.

Sensory disturbances, inhibitory deficits, and the P50 wave in schizophrenia.

Vlcek P, Bob P, Raboch J.

Neuropsychiatr Dis Treat. 2014 Jul 14;10:1309-15. doi: 10.2147/NDT.S64219. eCollection 2014. Review.

PMID:
25075189
[PubMed]
Free PMC Article
2.

P50 sensory gating in infants.

Ross AS, Hunter SK, Groth MA, Ross RG.

J Vis Exp. 2013 Dec 26;(82):50065. doi: 10.3791/50065.

PMID:
24430259
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Neurophysiologic effect of GWAS derived schizophrenia and bipolar risk variants.

Hall MH, Levy DL, Salisbury DF, Haddad S, Gallagher P, Lohan M, Cohen B, Ongür D, Smoller JW.

Am J Med Genet B Neuropsychiatr Genet. 2014 Jan;165B(1):9-18. doi: 10.1002/ajmg.b.32212. Epub 2013 Nov 8.

PMID:
24339136
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Smoking behaviour and mental health disorders--mutual influences and implications for therapy.

Minichino A, Bersani FS, Calò WK, Spagnoli F, Francesconi M, Vicinanza R, Delle Chiaie R, Biondi M.

Int J Environ Res Public Health. 2013 Oct 10;10(10):4790-811. doi: 10.3390/ijerph10104790. Review.

PMID:
24157506
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

An Open Trial of Relapse Prevention Therapy for Smokers With Schizophrenia.

Cather C, Dyer MA, Burrell HA, Hoeppner B, Goff DC, Evins AE.

J Dual Diagn. 2013;9(1):87-93.

PMID:
23750123
[PubMed]
Free PMC Article
6.

Cholinergic connectivity: it's implications for psychiatric disorders.

Scarr E, Gibbons AS, Neo J, Udawela M, Dean B.

Front Cell Neurosci. 2013 May 3;7:55. doi: 10.3389/fncel.2013.00055. eCollection 2013.

PMID:
23653591
[PubMed]
Free PMC Article
7.

Early sensory processing deficits predict sensitivity to distraction in schizophrenia.

Smucny J, Olincy A, Eichman LC, Lyons E, Tregellas JR.

Schizophr Res. 2013 Jun;147(1):196-200. doi: 10.1016/j.schres.2013.03.025. Epub 2013 Apr 13.

PMID:
23590872
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

A diagnostic model incorporating P50 sensory gating and neuropsychological tests for schizophrenia.

Shan JC, Liu CM, Chiu MJ, Liu CC, Chien YL, Hwang TJ, Lin YT, Hsieh MH, Jaw FS, Hwu HG.

PLoS One. 2013;8(2):e57197. doi: 10.1371/journal.pone.0057197. Epub 2013 Feb 27.

PMID:
23460831
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

P50 suppression and its neural generators in antipsychotic-naive first-episode schizophrenia before and after 6 months of quetiapine treatment.

Oranje B, Aggernaes B, Rasmussen H, Ebdrup BH, Glenthøj BY.

Schizophr Bull. 2013 Mar;39(2):472-80. doi: 10.1093/schbul/sbr183. Epub 2012 Jan 12.

PMID:
22241164
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Schizophrenia: vulnerability versus disease.

Tsuang MT, Stone WS, Faraone SV.

Dialogues Clin Neurosci. 2000 Sep;2(3):257-66.

PMID:
22034456
[PubMed]
Free PMC Article
11.

Toward a modern search for schizophrenia genes.

Leboyer M.

Dialogues Clin Neurosci. 2001 Jun;3(2):99-108.

PMID:
22033484
[PubMed]
Free PMC Article
12.

Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Jones CK, Byun N, Bubser M.

Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28. Review.

PMID:
21956443
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller RL, Wonodi I, Buchanan RW, Myers C, Heishman SJ, Yang J, Nye A.

Arch Gen Psychiatry. 2011 Dec;68(12):1195-206. doi: 10.1001/archgenpsychiatry.2011.83. Epub 2011 Aug 1.

PMID:
21810630
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

α7 Nicotinic Receptor Agonists: Potential Therapeutic Drugs for Treatment of Cognitive Impairments in Schizophrenia and Alzheimer's Disease.

Toyohara J, Hashimoto K.

Open Med Chem J. 2010 May 27;4:37-56. doi: 10.2174/1874104501004010037.

PMID:
21249164
[PubMed]
Free PMC Article
15.

Oxidative stress in schizophrenia: an integrated approach.

Bitanihirwe BK, Woo TU.

Neurosci Biobehav Rev. 2011 Jan;35(3):878-93. doi: 10.1016/j.neubiorev.2010.10.008. Epub 2010 Oct 23. Review.

PMID:
20974172
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Mouse model predicts effects of smoking and varenicline on event-related potentials in humans.

Rudnick ND, Strasser AA, Phillips JM, Jepson C, Patterson F, Frey JM, Turetsky BI, Lerman C, Siegel SJ.

Nicotine Tob Res. 2010 Jun;12(6):589-97. doi: 10.1093/ntr/ntq049. Epub 2010 Apr 15.

PMID:
20395358
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Varenicline and P50 auditory gating in medicated schizophrenic patients: a pilot study.

Waldo MC, Woodward L, Adler LE.

Psychiatry Res. 2010 Jan 30;175(1-2):179-80. doi: 10.1016/j.psychres.2009.01.025. Epub 2009 Dec 2.

PMID:
19959243
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

P50 sensory gating is related to performance on select tasks of cognitive inhibition.

Yadon CA, Bugg JM, Kisley MA, Davalos DB.

Cogn Affect Behav Neurosci. 2009 Dec;9(4):448-58. doi: 10.3758/CABN.9.4.448.

PMID:
19897797
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Smoking, Genetics and Schizophrenia: Evidence for Self Medication.

Leonard S, Mexal S, Freedman R.

J Dual Diagn. 2007 Nov 1;3(3-4):43-59.

PMID:
19122786
[PubMed]
Free PMC Article
20.

Proline affects brain function in 22q11DS children with the low activity COMT 158 allele.

Vorstman JA, Turetsky BI, Sijmens-Morcus ME, de Sain MG, Dorland B, Sprong M, Rappaport EF, Beemer FA, Emanuel BS, Kahn RS, van Engeland H, Kemner C.

Neuropsychopharmacology. 2009 Feb;34(3):739-46. doi: 10.1038/npp.2008.132. Epub 2008 Sep 3.

PMID:
18769474
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk